Stockscreener 앱 받기
0.9679
12.55%
0.1079
시간 외 거래:
1.04
0.0721
+7.45%
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World
Palatin reports positive Phase 2b results in diabetic nephropathy - Yahoo Finance
First Patient Dosed in Phase 2 Clinical Study of Palatin's Breme - GuruFocus.com
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PR Newswire
Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - MSN
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - The Eastern Progress Online
Palatin Technologies Secures $3.4M Through Strategic Warrant Exercise Deal, Issues New Warrants - StockTitan
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - The Eastern Progress Online
Palatin Technologies (BUE:PTN) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com
Thinking about buying stock in MedAvail Holdings, Trio-Tech Inte - GuruFocus.com
PTN (Palatin Technologies) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
PTN (Palatin Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Palatin Technologies stock stays Buy rated after completing Phase 2 enrollment in UC trial - Investing.com UK
Palatin Announces Completion of Patient Enrollment in Phase 2 St - GuruFocus.com
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Palatin Completes Phase 2 Enrollment for Novel Ulcerative Colitis Pill, Data Due Q1 2025 - StockTitan
Palatin Technologies (FRA:PTN) Retained Earnings : €-405.08 Mil (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Graham Number : €N/A (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Float Percentage Of Total Sh - GuruFocus.com
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleco - GuruFocus.com
Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Quarterly 10-Q Report - Quartzy
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges - GuruFocus.com
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... By GuruFocus - Investing.com Canada
Palatin Technologies Shifts Focus to Obesity Treatments - TipRanks
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - The Malaysian Reserve
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financi - GuruFocus.com
Indo-Asian News Service - IANS India Pvt Ltd
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - BioSpace
Palatin Technologies Sets Q1 2025 Earnings Release for November 14 | PTN Stock News - StockTitan
Palatin Technologies (BUE:PTN) 9-Day RSI : N/A (As of Nov. 06, 2024) - GuruFocus.com
Palatin Technologies (BUE:PTN) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PR Newswire
HC Wainwright Reaffirms Buy Rating for Palatin Technologies (NYSEAMERICAN:PTN) - Defense World
Palatin Receives Notice of Non-Compliance from NYSE American - GuruFocus.com
Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - Marketscreener.com
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - StockTitan
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - GuruFocus.com
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium - BioSpace
PTNPalatin Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium - BioSpace
Palatin Presents Foundational Data on Novel and Highly Selective - GuruFocus.com
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium – Company AnnouncementFT.com - Financial Times
Dry Eye Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin faces NYSE American non-compliance notice By Investing.com - Investing.com Australia
Palatin faces NYSE American non-compliance notice - Investing.com
Palatin Technologies (NYSEAMERICAN:PTN) Issues Quarterly Earnings Results - Defense World
Palatin Technologies, Inc. (AMEX:PTN) Q4 2024 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc. (PTN) is a good investment, but the stock may be undervalued - US Post News
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 By Investing.com - Investing.com South Africa
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 - Investing.com Canada
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ... - Yahoo Finance
2.88%
2.65%
자본화:
|
볼륨(24시간):